SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?

Authors

  • Hitesh C Patel National Institute of Health Research (NIHR), Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom
  • Carl Hayward National Institute of Health Research (NIHR), Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom
  • Carlo Di Mario National Institute of Health Research (NIHR), Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom

Abstract

Resistant hypertension is, by definition, a challenge to most physicians treating hypertension. Renal sympathetic denervation has shown promising early results in treating this condition. The SYMPLICITY HTN-3 is the most recent trial to report the effects of this technique on resistant hypertension. This review discusses this study and its surprising neutral results before ending with an overview of key lessons learned. 

Downloads

Published

2017-06-02

Issue

Vol. 2014 No. 1 (2014)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.